The Analyst Landscape: 8 Takes On RxSight
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have provided ratings for RxSight (NASDAQ:RXST), with sentiments ranging from bullish to bearish. The average 12-month price target for RXST is $42.38, with a high of $54.00 and a low of $30.00, marking a 3.37% increase from the previous target of $41.00. Analysts from firms like Oppenheimer, Needham, Wells Fargo, Stifel, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's market performance. RxSight, a medical technology company, has shown a revenue growth of 75.97% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -55.93%, ROE of -7.79%, and ROA of -6.58%. The company has a low debt-to-equity ratio of 0.02.
January 29, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RxSight has received varied analyst ratings with an average 12-month price target of $42.38. The company has demonstrated significant revenue growth but struggles with profitability and asset utilization.
The positive revenue growth rate of 75.97% is likely to be viewed favorably by investors, potentially leading to a short-term increase in stock price. However, concerns about net margin, ROE, and ROA could temper gains. The recent increase in the average price target suggests a bullish sentiment among analysts, which may influence investor perception and drive short-term price movement.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100